ChromaDex (NASDAQ: CDXC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-02 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.090 | -0.110 | -0.0200 | ||||
REV | 17.230M | 17.259M | 29.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ChromaDex (NASDAQ: CDXC) through any online brokerage.
Other companies in ChromaDex’s space includes: Harvard Bioscience (NASDAQ:HBIO), Codex DNA (NASDAQ:DNAY), Personalis (NASDAQ:PSNL), IsoPlexis (NASDAQ:ISO) and Quoin Pharmaceuticals (NASDAQ:QNRX).
The latest price target for ChromaDex (NASDAQ: CDXC) was reported by HC Wainwright & Co. on Tuesday, June 7, 2022. The analyst firm set a price target for 7.00 expecting CDXC to rise to within 12 months (a possible 300.00% upside). 6 analyst firms have reported ratings in the last year.
The stock price for ChromaDex (NASDAQ: CDXC) is $1.75 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for ChromaDex.
ChromaDex’s Q2 earnings are confirmed for Tuesday, August 2, 2022.
There is no upcoming split for ChromaDex.
ChromaDex is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.